News

Modification of Criteria for Diagnosing Irritable Bowel Syndrome in Clinical Practice

20. 9. 2022 Source: Irritable Bowel Syndrome

The Rome criteria for diagnosing disorders of gut-brain interaction (DGBI) have recently been modified due to discrepancies with their use in clinical practice. The Rome Foundation board has created modified Rome IV diagnostic criteria. When caring for patients with DGBI, including irritable bowel syndrome (IBS), it will be possible to diagnose even with shorter duration and lower frequency of symptoms.

Prediabetes as a Risk Factor for Overall Mortality and Development of CVD

Prediabetes represents a glucose metabolism disorder with a high risk of developing diabetes. According to the expert panel of the American Diabetes Association (ADA), this risk is up to 70%. A…

16. 9. 2022 Source: Modern Treatment of Diabetes

XR vs. IR Form of Metformin −⁠ It’s Not Just About Gastrointestinal Tolerability

It is well known that the XR form of metformin shows better gastrointestinal tolerability. However, research suggests that the two forms of metformin −⁠ XR and IR −⁠ differ in other aspects as well. In…

16. 9. 2022 Source: Modern Treatment of Diabetes

What affects the elimination of bisoprolol in diabetics and patients with acute coronary syndrome?

Beta-blockers are widely used to reduce cardiovascular (CV) risk in a number of diseases. However, information about the pharmacokinetics of these drugs is still far from complete. Two studies…

16. 9. 2022 Source: Cardiovascular Continuum

What is the Impact of Bisoprolol on Plasma Concentrations of Dabigatran

Many patients on anticoagulant therapy with dabigatran also use the beta-blocker bisoprolol. The Slovak prospective observational study was based on the assumption that bisoprolol, as a significant…

16. 9. 2022 Source: Cardiovascular Continuum

Interchangeability of Diosmin and Micronized Purified Flavonoid Fraction

Among the medicinal products reimbursed for chronic venous disease, those containing micronized diosmin (Diozen 180 tbl.) have been newly included. Which substances are available for this indication,…

16. 9. 2022 Source: Venous Insufficiency

Ceftaroline as a Treatment Option for MRSA-Induced Sepsis?

A recently published study by a team of authors from several American institutions focused on comparing the efficacy and safety of the 5th generation cephalosporin ceftaroline with the standard of…

16. 9. 2022 Source: Anti-Infectives

Association of Low TSH Levels in Hypothyroidism Therapy with Mortality Risk

Community surveys indicate that up to 53% of patients treated for hypothyroidism have serum thyroid-stimulating hormone (TSH) levels outside the normal range at some point. The negative effect of TSH…

14. 9. 2022 Source: Thyroid Disorders

Correlation of Levothyroxine Dose with Autoimmune Antibody Titer in Primary Hypothyroidism

The relationship between the level of antithyroid antibodies and the required dose of levothyroxine in substitution for autoimmune hypothyroidism is a poorly explored question. Therefore, a…

14. 9. 2022 Source: Thyroid Disorders

Bimekizumab vs. Adalimumab in the Treatment of Moderate to Severe Plaque Psoriasis

Bimekizumab is a humanized IgG1 monoclonal antibody that selectively inhibits interleukins 17A and 17F for the treatment of moderate to severe plaque psoriasis in adults for whom systemic therapy is…

12. 9. 2022 Source: Psoriasis

How to Most Effectively Delay Skeletal Events in Patients with Bone Metastases from Solid Tumors?

In a randomized Phase III study, the effectiveness of denosumab and zoledronic acid in preventing skeletal events in patients with multiple myeloma or solid tumors (excluding breast and prostate…

12. 9. 2022 Source: Prevention of Bone Events

Effect of Denosumab and Zoledronic Acid on Overall Survival in Patients with Metastatic Lung Cancer

In 30-40% of patients with non-small cell lung cancer (NSCLC), bone metastases develop during the course of the disease, causing so-called skeletal-related events (SREs). These events cause pain,…

12. 9. 2022 Source: Prevention of Bone Events

Doc. Debora Karetová: Do Not Underestimate the Complexity of CHVO Treatment and Early Stages of the Disease

Are you applying the optimal approach to the treatment of chronic venous disease? What do the new Czech recommendations bring? And what is the current role of venopharmacs in treatment management?…

12. 9. 2022 Source: Venous Insufficiency

Brigatinib in Patients with ALK+ NSCLC –⁠ Final Results of the J-ALTA Clinical Study

At this year's American Society of Clinical Oncology (ASCO) conference held in Chicago in early June 2022, the final results of the J-ALTA clinical study were presented. So how did brigatinib perform…

12. 9. 2022 Source: Non-Small Cell Lung Cancer

Impact of Depth of Treatment Response on Outcomes of ALK+ NSCLC Treatment with Brigatinib and Crizotinib

Brigatinib inhibits anaplastic lymphoma kinase (ALK) and its notable advantage is its strong effect in patients who have developed resistance during treatment with other ALK inhibitors. It has…

12. 9. 2022 Source: Non-Small Cell Lung Cancer

1 … 45 46 47 48 49 … 115

Back Filter by speciality

Remove filters

Popular this week